Citation Impact
Citing Papers
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
2010
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
2009
Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
2007
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
2013
Re-establishing immunological self-tolerance in autoimmune disease
2012 StandoutNobel
The Nuclear Factor NF- B Pathway in Inflammation
2009 Standout
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
2010
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009
Mechanisms of SARS-CoV-2 entry into cells
2021 Standout
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
1999 Standout
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
New therapies for treatment of rheumatoid arthritis
2007
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study
2006
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
CD28 Costimulation: From Mechanism to Therapy
2016
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
2005
Pharmacological treatment of established rheumatoid arthritis
2003
An Enigmatic Tail of CD28 Signaling
2010
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis
2007
The problem of choice: current biologic agents and future prospects in RA
2013
Juvenile idiopathic arthritis
2007 Standout
Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis
1995
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Patient-Driven Outcomes in Rheumatoid Arthritis
2009
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
1999 Standout
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
2016
CEACAM1: contact-dependent control of immunity
2006
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
2007
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
2007 Standout
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
2011
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
2008
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
2012
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Abatacept for severe anti–tumor necrosis factor α refractory juvenile idiopathic arthritis–related uveitis
2010
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
IL-6 as a keystone cytokine in health and disease
2015 Standout
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Abatacept
2006
Forget personalised medicine and focus on abating disease activity
2012
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
2006
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
2006
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases
2007
T cell–directed therapies: lessons learned and future prospects
2006
Graphical Tools for Network Meta-Analysis in STATA
2013 Standout
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
2016
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
2005
Graves' Ophthalmopathy
2010 Standout
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
2006
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
1999
Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications
1996
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
2006
Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study
2009
Systemic Lupus Erythematosus
2011 Standout
The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial
2010
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
2008
Abatacept: A Novel Treatment for Moderate‐to‐Severe Rheumatoid Arthritis
2007
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
2007
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Type 1 diabetes
2013 Standout
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
2008
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Virus-induced autoantibody response to a transgenic viral antigen
1990 StandoutNatureNobel
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Abatacept therapy and safety management
2009
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
2007
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
2008
Rheumatoid arthritis
2010 Standout
Tryptophan degradation in autoimmune diseases
2007
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies
2015
Rheumatoid arthritis
2001
CTLA‐4: a key regulatory point in the control of autoimmune disease
2008
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis
2016 StandoutNobel
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept
2008
Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
2010
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
T-cell-targeted therapies in rheumatoid arthritis
2006
Structure and signalling in the IL-17 receptor family
2009 Standout
Current management of juvenile idiopathic arthritis
2006
FcRn: the neonatal Fc receptor comes of age
2007 Standout
Biologic therapy and pregnancy outcomes in women with rheumatic diseases
2009
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
2008
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Rheumatoid Arthritis
2008
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
2021
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
2009 StandoutNobel
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
2008
Advances in targeted therapeutic agents
2010
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
2000
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
The clinical utility of inhibiting CD28‐mediated costimulation
2009
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study
2017
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
2008
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
2006
Disease activity measures for rheumatoid arthritis.
2008
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
The Biology and Detection of Immune Complexes
1980
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Monomeric Fc Fusions
2006
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
2012 StandoutNobel
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Generic quality-of-life assessment in rheumatoid arthritis.
2007
Works of J. Box being referenced
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
2005
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis
1992
Cardiopulmonary Manifestations of Progressive Systemic Sclerosis
1979